It was observed that GLUT1 expression increased with the malignancy of tumors; GLUT4 expression decreased gradually with tumor progression; GLUT6 showed the highest expression in low-grade gliomas, with expression levels in tumor tissues higher than those in normal brain tissues; SREBP2 expression decreased gradually with tumor progression (Fig. 1f). Here, SLC2A4 is linked to central nervous system cancer.